{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:06:57Z","timestamp":1781626017074,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","award":["Innovation Accelerator Fund"],"award-info":[{"award-number":["Innovation Accelerator Fund"]}],"id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","award":["Innovation Accelerator Fund"],"award-info":[{"award-number":["Innovation Accelerator Fund"]}],"id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ontario Ministry of Research and Innovation"},{"name":"Leukemia and Lymphoma Society SCOR program","award":["7029-23"],"award-info":[{"award-number":["7029-23"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adoptive cell transfer (ACT) of tumour-infiltrating lymphocytes (TIL) is an investigational treatment for solid tumours, with preliminary results showing objective clinical responses in some metastatic melanoma patients. The ability to sequence and track the T cell repertoire throughout ACT of TILs provides a method to identify T cell repertoire features associated with patients\u2019 benefit from ACT. Identification of response biomarkers for patients receiving ACT of TILs has been limited. Conflicting evidence is observed in biomarkers such as the number of TILs in the infusion product, with some studies suggesting a relationship with response and others not. Meanwhile, certain potential biomarkers, such as the diversity of the post-infusion peripheral repertoire, have not yet been studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we sought to determine 1) the efficacy of using CapTCR-seq to track TILs in serial blood draws over the course of ACT immunotherapy 2) whether peripheral T cell repertoire statistics are associated with ACT response. In this study, 9 patients with cutaneous (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097) or mucosal (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092) melanoma received TIL ACT after chemotherapeutic depletion. Hybrid-capture CapTCR-seq was conducted on pre-\/post-transfer peripheral blood mononuclear cells (PBMC) and cell-free DNA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comparison between PBMC DNA, PBMC RNA, and circulating free DNA (cfDNA) repertoires demonstrated an increased presence of shared T cell clonotypes post-infusion when compared with baseline samples. Higher abundance of TIL clonotypes in the PBMC baseline and post-infusion DNA T cell repertoires and the presence of shared DNA T cell clonotypes between timepoints was seen in responders when compared with non-responders according to RECIST criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results demonstrate effective tracking methodologies and suggest a predictive role for baseline repertoire statistics in response to the ACT of TILs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-025-01583-w","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:26:19Z","timestamp":1765880779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delineation and monitoring of the T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Cameron","family":"Kerr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Nabbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Sotov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumedha","family":"Sudhaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus O.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"17","key":"1583_CR1","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","volume":"19","author":"MJ Besser","year":"2013","unstructured":"Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res. 2013;19(17):4792\u2013800. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0380.","journal-title":"Clin Cancer Res"},{"issue":"5594","key":"1583_CR2","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1076514","volume":"298","author":"ME Dudley","year":"2002","unstructured":"Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850\u20134. https:\/\/doi.org\/10.1126\/science.1076514.","journal-title":"Science"},{"issue":"18","key":"1583_CR3","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1158\/1078-0432.ccr-17-3649","volume":"24","author":"MA Forget","year":"2018","unstructured":"Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, et al. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res. 2018;24(18):4416\u201328. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-3649.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1583_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/CJI.0b013e31826e8f5f","volume":"35","author":"S Pilon-Thomas","year":"2012","unstructured":"Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012;35(8):615\u201320. https:\/\/doi.org\/10.1097\/CJI.0b013e31826e8f5f.","journal-title":"J Immunother"},{"issue":"24","key":"1583_CR5","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","volume":"18","author":"LG Radvanyi","year":"2012","unstructured":"Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18(24):6758\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1177.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1583_CR6","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0116.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1583_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, Gartner J, Jia L, Trebska-McGowan K, Somerville RP, Robbins PF, Rosenberg SA, Goff SL, Feldman SA. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724\u201330. https:\/\/doi.org\/10.1038\/s41591-018-0040-8.","journal-title":"Nat Med"},{"issue":"8","key":"1583_CR8","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27(8):1410\u20138. https:\/\/doi.org\/10.1038\/s41591-021-01462-y.","journal-title":"Nat Med"},{"issue":"14","key":"1583_CR9","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","volume":"33","author":"S Stevanovi\u0107","year":"2015","unstructured":"Stevanovi\u0107 S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus\u2013targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543\u201350. https:\/\/doi.org\/10.1200\/JCO.2014.58.9093.","journal-title":"J Clin Oncol"},{"issue":"6184","key":"1583_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4\u2009+\u2009T cells in a patient with epithelial cancer. Science. 2014;344(6184):641\u20135. https:\/\/doi.org\/10.1126\/science.1251102.","journal-title":"Science"},{"issue":"8","key":"1583_CR11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen\u2013specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537\u201344. https:\/\/doi.org\/10.1182\/blood-2008-12-195792.","journal-title":"Blood"},{"issue":"5","key":"1583_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"JC Beltra","year":"2020","unstructured":"Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, et al. Developmental relationships of four exhausted CD8\u2009+\u2009T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52(5):825-41.e8. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.014.","journal-title":"Immunity"},{"issue":"23","key":"1583_CR13","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1158\/0008-5472.CAN-12-0588","volume":"72","author":"QJ Wang","year":"2012","unstructured":"Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res. 2012;72(23):6119\u201329. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0588.","journal-title":"Cancer Res"},{"issue":"6230","key":"1583_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62\u20138. https:\/\/doi.org\/10.1126\/science.aaa4967.","journal-title":"Science"},{"issue":"2","key":"1583_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s43018-019-0022-x","volume":"1","author":"S Valpione","year":"2020","unstructured":"Valpione S, Galvani E, Tweedy J, Mundra PA, Banyard A, Middlehurst P, Barry J, Mills S, Salih Z, Weightman J, Gupta A, Gremel G, Baenke F, Dhomen N, Lorigan PC, Marais R. Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer. 2020;1(2):210\u201321. https:\/\/doi.org\/10.1038\/s43018-019-0022-x.","journal-title":"Nat Cancer"},{"issue":"2","key":"1583_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"23","key":"1583_CR17","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.ccr-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412\u201320. https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-1624.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1583_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/CJI.0b013e318209c94c","volume":"34","author":"O Itzhaki","year":"2011","unstructured":"Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, et al. Establishment and large-scale expansion of minimally cultured \u201cyoung\u201d tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother. 2011;34(2):212\u201320. https:\/\/doi.org\/10.1097\/CJI.0b013e318209c94c.","journal-title":"J Immunother"},{"key":"1583_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00044","author":"JE Mullinax","year":"2018","unstructured":"Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, et al. Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. Front Oncol. 2018. https:\/\/doi.org\/10.3389\/fonc.2018.00044.","journal-title":"Front Oncol"},{"issue":"12","key":"1583_CR20","doi-asserted-by":"publisher","first-page":"7125","DOI":"10.4049\/jimmunol.173.12.7125","volume":"173","author":"PF Robbins","year":"2004","unstructured":"Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ, Rosenberg SA. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173(12):7125\u201330. https:\/\/doi.org\/10.4049\/jimmunol.173.12.7125.","journal-title":"J Immunol"},{"issue":"8","key":"1583_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aal2568","volume":"2","author":"AG Chapuis","year":"2017","unstructured":"Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya KC, Lai IP, et al. Tracking the fate and origin of clinically relevant adoptively transferred CD8 <Superscript>+<\/Superscript>T cells in vivo. Sci Immunol. 2017;2(8):eaal2568. https:\/\/doi.org\/10.1126\/sciimmunol.aal2568.","journal-title":"Sci Immunol"},{"issue":"3","key":"1583_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/01.cji.0000158855.92792.7a","volume":"28","author":"J Huang","year":"2005","unstructured":"Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005;28(3):258\u201367. https:\/\/doi.org\/10.1097\/01.cji.0000158855.92792.7a.","journal-title":"J Immunother"},{"issue":"23","key":"1583_CR23","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1182\/bloodadvances.2017014639","volume":"2","author":"DT Mulder","year":"2018","unstructured":"Mulder DT, Mah\u00e9 ER, Dowar M, Hanna Y, Li T, Nguyen LT, Butler MO, Hirano N, Delabie J, Ohashi PS, Pugh TJ. CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. Blood Adv. 2018;2(23):3506\u201314. https:\/\/doi.org\/10.1182\/bloodadvances.2017014639.","journal-title":"Blood Adv"},{"issue":"9","key":"1583_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116190","volume":"44","author":"S Soleimani","year":"2025","unstructured":"Soleimani S, Li X, Wang BX, Pedersen S, Bruce JP, Eagles J, et al. T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab. Cell Rep. 2025;44(9):116190. https:\/\/doi.org\/10.1016\/j.celrep.2025.116190.","journal-title":"Cell Rep"},{"issue":"5","key":"1583_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00262-019-02307-x","volume":"68","author":"LT Nguyen","year":"2019","unstructured":"Nguyen LT, Saibil SD, Sotov V, Le MX, Khoja L, Ghazarian D, Bonilla L, Majeed H, Hogg D, Joshua AM, Crump M, Franke N, Spreafico A, Hansen A, Al-Habeeb A, Leong W, Easson A, Reedijk M, Goldstein DP, Butler MO. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunol Immunother. 2019;68(5):773\u201385. https:\/\/doi.org\/10.1007\/s00262-019-02307-x.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"1583_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"1, Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, Chudakov DM. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12(5):380\u20131. https:\/\/doi.org\/10.1038\/nmeth.3364.","journal-title":"Nat Methods"},{"issue":"6","key":"1583_CR27","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.3892\/ol.2016.4465","volume":"11","author":"K Tamura","year":"2016","unstructured":"Tamura K, Hazama S, Yamaguchi R, Imoto S, Takenouchi H, Inoue Y, Kanekiyo S, Shindo Y, Miyano S, Nakamura Y, Kiyotani K. Characterization of the T cell repertoire by deep T cell receptor sequencing in tissues and blood from patients with advanced colorectal cancer. Oncol Lett. 2016;11(6):3643\u20139. https:\/\/doi.org\/10.3892\/ol.2016.4465.","journal-title":"Oncol Lett"},{"issue":"4","key":"1583_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/path.4260","volume":"231","author":"RO Emerson","year":"2013","unstructured":"Emerson RO, Sherwood AM, Rieder MJ, Guenthoer J, Williamson DW, Carlson CS, Drescher CW, Tewari M, Bielas JH, Robins HS. High-throughput sequencing of T\u2010cell receptors reveals a homogeneous repertoire of tumour\u2010infiltrating lymphocytes in ovarian cancer. J Pathol. 2013;231(4):433\u201340. https:\/\/doi.org\/10.1002\/path.4260.","journal-title":"J Pathol"},{"key":"1583_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954078","author":"K Peng","year":"2022","unstructured":"Peng K, Moore J, Vahed M, Brito J, Kao G, Burkhardt AM, et al. PyTCR: a comprehensive and scalable solution for TCR-Seq data analysis to facilitate reproducibility and rigor of immunogenomics research. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.954078.","journal-title":"Front Immunol"},{"issue":"6","key":"1583_CR30","doi-asserted-by":"publisher","first-page":"e004512","DOI":"10.1136\/jitc-2022-004512","volume":"10","author":"X Wang","year":"2022","unstructured":"Wang X, Muzaffar J, Kirtane K, Song F, Johnson M, Schell MJ, Li J, Yoder SJ, Conejo-Garcia JR, Guevara-Patino JA, Bonomi M, Bhateja P, Rocco JW, Steuer CE, Saba NF, Chung CH. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022;10(6):e004512. https:\/\/doi.org\/10.1136\/jitc-2022-004512.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1583_CR31","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1182\/blood-2005-03-1082","volume":"106","author":"WN Haining","year":"2005","unstructured":"Haining WN, Neuberg DS, Keczkemethy HL, Evans JW, Rivoli S, Gelman R, Rosenblatt HM, Shearer WT, Guenaga J, Douek DC, Silverman LB, Sallan SE, Guinan EC, Nadler LM. Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood. 2005;106(5):1749\u201354. https:\/\/doi.org\/10.1182\/blood-2005-03-1082.","journal-title":"Blood"},{"issue":"47","key":"1583_CR32","doi-asserted-by":"publisher","first-page":"18484","DOI":"10.1073\/pnas.0806487105","volume":"105","author":"SE Hamilton","year":"2008","unstructured":"Hamilton SE, Jameson SC. The nature of the lymphopenic environment dictates protective function of homeostatic-memory CD8 +T cells. Proc Natl Acad Sci USA. 2008;105(47):18484\u20139. https:\/\/doi.org\/10.1073\/pnas.0806487105.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1583_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0070-4","volume":"3","author":"MA Postow","year":"2015","unstructured":"Postow MA, Manuel M, Wong P, Yuan J, Dong Z, Liu C, et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J Immunother Cancer. 2015;3(1):23. https:\/\/doi.org\/10.1186\/s40425-015-0070-4.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"1583_CR34","doi-asserted-by":"publisher","first-page":"e1494112","DOI":"10.1080\/2162402x.2018.1494112","volume":"7","author":"BA Kansy","year":"2018","unstructured":"Kansy BA, Shayan G, Jie HB, Gibson SP, Lei YL, Brandau S, et al. T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. Oncoimmunology. 2018;7(11):e1494112. https:\/\/doi.org\/10.1080\/2162402x.2018.1494112.","journal-title":"Oncoimmunology"},{"issue":"9","key":"1583_CR35","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","volume":"20","author":"L Robert","year":"2014","unstructured":"Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, et al. CTLA4 blockade broadens the peripheral T-Cell receptor repertoire. Clin Cancer Res. 2014;20(9):2424\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2648.","journal-title":"Clin Cancer Res"},{"key":"1583_CR36","unstructured":"Kerr C et al. Delineation and monitoring of T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma. Github. 2019.\u00a0https:\/\/github.com\/pughlab\/CapTCR-TIL-Tracking."},{"key":"1583_CR37","unstructured":"Kerr C et al. Delineation and monitoring of T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma. TIGERdb: T-cell & ImmunoGlobulin Epitope Receptor DataBase. 2025. https:\/\/tigerdb.ca\/public\/data\/96173e3f-1ae0-451a-9833-6af717f33b8d."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-025-01583-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:16:40Z","timestamp":1781623000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-025-01583-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1186\/s13073-025-01583-w","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University Health Network Research Ethics Board under application #11\u20130683.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TJP and DTM are inventors on patents held by the University Health Network regarding hybrid-capture sequencing for determining immune cell clonality.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}